PanK Small-Molecule Modulators for Tissue-Specific CoA Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective modulators of pantothenate kinase (PanK) to investigate the role of Coenzyme A (CoA) levels in diseases such as PanK-associated neurodegeneration (PKAN) and diabetes, as existing tools are insufficient for understanding the relationship between CoA levels and neurodegeneration, and altering CoA levels can impact oxidative metabolism and glucose homeostasis.
Innovation Solution
Development of small molecule modulators of PanK, including compounds with specific structural features, to modulate CoA levels and treat disorders associated with PanK activity, such as PKAN and diabetes, by administering effective amounts of these compounds to subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule modulators of PanK are developed, then the ability to investigate CoA levels in diseases is improved, but the complexity of the research tools increases
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to modulate PanK activity. These molecules serve as tools to indirectly investigate CoA levels by controlling the enzyme that produces CoA, rather than directly measuring CoA itself. This approach simplifies the research methodology while maintaining investigative reliability.
2Reliability
If PanK activity is modulated to treat PKAN, then neuronal CoA levels can be increased, but the risk of off-target effects on other tissues increases
Solution Approach 1:
The patent exploits the differential expression and function of PanK isoforms in different tissues. By designing modulators that preferentially affect PanK2 (the isoform mutated in PKAN and highly expressed in neuronal tissue), the treatment can locally improve neuronal CoA levels while minimizing disruption to CoA homeostasis in other tissues that rely on different PanK isoforms.
3Reliability
If PanK inhibitors are used to treat diabetes, then hepatic CoA levels can be reduced to normalize glucose homeostasis, but the risk of metabolic disruption increases
Solution Approach 1:
The patent applies partial inhibition of PanK activity in diabetic conditions rather than complete inhibition. By using modulators that reduce but do not eliminate PanK activity, the treatment achieves the therapeutic goal of lowering hepatic CoA levels to normalize glucose homeostasis while maintaining sufficient PanK function to prevent severe metabolic disruption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modulators effectively regulate CoA levels, providing therapeutic potential for treating disorders like PKAN and diabetes by modulating PanK activity and improving metabolic pathways.
Implementation Method 1
Pantothenate Kinase (PanK, EC 2.7.1.33) catalyzes the biochemical conversion of pantothenate (vitamin B5) to phosphopantothenate
Data Source
AI summary
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.